Regulatory approval

Published by the Health Service Executive. Approved

Obinutuzumab in combination with bendamustine is indicated for the treatment of patients with previously untreated advanced follicular lymphoma.

This is written in the approval document.

Reimbursement

ODMS

Citation

Obinutuzumab and Bendamustine Therapy - 28 day cycle, 2026, version number 4, NCCP National SACT Regimen, NCCP, viewed 02/08/2026, https://healthservice.hse.ie/documents/8392/424_Obinutuzumab_and_Bendamustine.pdf

Therapeutic response

Precision oncology relationships for therapeutic response derived from this regulatory approval.

Organizations	Biomarkers	Cancer types	Therapies
HSE (1)	CD20 +	Follicular Lymphoma	Bendamustine, Obinutuzumab

Contributions

Date	Contributor	Description
2026-08-02	Van Allen lab	Initial curation of into moalmanac-db
2019-05-01	Health Service Executive	Indication approved for reimbursement.